What's Happening

Private-equity firm TPG is exploring a sale of Lyric, a healthcare software company whose technology helps insurers identify and prevent inaccurate medical claims payments.

The potential transaction could value Lyric at approximately $5 billion, according to people familiar with the discussions. TPG is working with JPMorgan Chase on the possible sale, although there is no guarantee that a transaction will ultimately happen. (Reuters)

Lyric has become an important technology provider to large U.S. health insurers. Companies including UnitedHealth, CVS and Humana use its software to identify claims that may have been paid incorrectly, giving insurers a way to detect payment errors and potentially reduce unnecessary healthcare spending. (Reuters)

The potential sale also comes at an important moment for the broader software industry. Healthcare software businesses that were once considered highly defensible are now being reassessed because of the rapid development of artificial intelligence, which could potentially allow new competitors to perform some of the same functions at a lower cost. (Reuters)

Lyric Helps Insurers Find Incorrect Payments

The company focuses on payment integrity

Lyric's software is designed to help health insurers identify inaccurate medical claims payments.

Healthcare claims are extremely complex. A single claim can involve a patient's treatment, diagnosis, provider, insurer rules, billing codes and contractual reimbursement requirements.

Errors can occur in many different ways.

A health insurer might pay too much, pay for something that should not have been covered, pay the wrong provider or incorrectly process a claim according to its contract.

Lyric's technology helps insurers identify these types of problems.

Its Customers Include Major U.S. Insurers

The company has relationships with industry giants

The company has relationships with some of the largest names in American healthcare, including UnitedHealth, CVS and Humana. (Reuters)

That customer base is commercially important because even small improvements in claims accuracy can translate into substantial financial effects when applied across millions of claims.

For an insurer, the ability to identify payment errors is therefore directly connected to controlling medical costs and improving the efficiency of its operations.

TPG Acquired the Business for $2.2 Billion

Lyric was previously part of Change Healthcare

TPG acquired Lyric in 2022 for approximately $2.2 billion.

At the time, the business was known as ClaimsXten and was part of Change Healthcare. Change Healthcare was later acquired by UnitedHealth in a deal worth approximately $13 billion. (Reuters)

TPG acquired ClaimsXten partly in connection with efforts to address potential antitrust concerns surrounding the UnitedHealth transaction.

In 2023, TPG rebranded the business as Lyric. (Reuters)

The possible sale would therefore represent a significant increase in value from TPG's original acquisition price.

Lyric Has Expanded Under TPG

Revenue growth has accelerated

TPG has previously said that Lyric experienced a significant acceleration in revenue growth after the acquisition.

The precise size of that growth has not been disclosed publicly. (Reuters)

TPG has also said that Lyric has benefited from the deployment of AI and that its large, data-rich business could become even more valuable as AI capabilities improve. (Reuters)

That creates an interesting contrast in the potential sale.

AI is helping Lyric improve its technology, but AI is simultaneously creating new competitors and raising questions about whether specialized software businesses can maintain their historical valuations.

Lyric Generates About $250 Million in Annual EBITDA

The business has strong cash-generation potential

Lyric currently generates approximately $250 million in annual EBITDA, according to people familiar with the matter. (Reuters)

Using a valuation of $5 billion would imply a multiple of approximately 20 times EBITDA.

That is a significant valuation for a healthcare software business and reflects expectations around both the company's existing earnings and its future growth potential.

The valuation is not final, however, because the sale process is still exploratory.

AI Is Changing How Buyers Value Software Companies

Specialized software is no longer automatically considered safe

The potential Lyric transaction comes as the software market adjusts to rapid advances in AI.

Earlier this year, concerns about AI disruption contributed to a selloff across the software sector. (Reuters)

Investors and potential buyers began asking a difficult question:

If AI can eventually perform the same task as a specialized software platform, how much should that platform be worth today?

That concern applies particularly to software companies whose products perform highly structured information-processing tasks.

Claims management and payment-integrity software fall into that category because they rely heavily on large datasets and algorithms to identify patterns and errors.

Lyric's Data Could Also Be an Advantage

AI creates both a threat and an opportunity

Lyric's business is unusually data intensive.

TPG has argued that the company's large dataset gives it an advantage as AI becomes more capable. (Reuters)

The logic is relatively straightforward.

AI models need large quantities of relevant information to identify patterns and improve performance. A company that has spent years collecting healthcare claims data and building systems around those data may have an important advantage over a new competitor starting from scratch.

That means AI does not necessarily make Lyric's existing technology obsolete.

It could make the company's underlying data and technology more valuable, provided Lyric can use AI effectively.

But AI-Native Competitors Are Creating Valuation Risk

New companies may solve the same problem differently

Potential buyers of software companies are increasingly examining whether AI-native competitors could perform similar functions at lower prices. (Reuters)

An AI-native company can potentially build its product around newer technologies from the beginning rather than modifying an older software architecture.

If such companies can offer similar or better performance at a lower cost, established software providers may face pressure on pricing and market share.

That is one reason buyers are becoming more cautious about paying extremely high multiples for software businesses.

Claritev Shows What Investors Are Worried About

Public-market valuations have already been affected

The experience of smaller public peer Claritev illustrates the concern.

Claritev's stock fell approximately 80% between September 2025 and May 2026 as investors became worried about AI disruption to healthcare software companies. (Reuters)

The stock has since recovered somewhat, but Reuters reported that it remains below $38 per share, compared with about $72 one year earlier. (Reuters)

That illustrates how quickly investor expectations can change when a technology shift threatens the assumptions behind a software company's valuation.

For Lyric, the possible $5 billion valuation therefore reflects not only current earnings but also a bet that the business can remain highly valuable in an AI-driven market.

Healthcare Payment Integrity Is a Large Opportunity

Insurers are under constant pressure to control spending

Payment integrity matters because healthcare spending in the United States is enormous.

Even relatively small levels of inaccurate or unnecessary payments can translate into significant costs when multiplied across the entire insurance system.

Insurers therefore have strong incentives to invest in technology that helps them identify claims that should be reviewed or corrected.

This gives Lyric a business model tied directly to a persistent healthcare problem: making sure money is paid correctly for medical care.

The Customer Base Creates Stickiness

Switching claims software can be difficult

Software that becomes deeply integrated into an insurer's claims process can be difficult to replace.

An insurer using the system needs to consider the technology itself, data integration, workflows, employee processes and the financial consequences of changing vendors.

That can make successful healthcare software businesses relatively sticky once they become embedded in a customer's operations.

Lyric's relationships with several major insurers therefore represent more than revenue. They also indicate that its technology is integrated into important parts of customers' healthcare-finance infrastructure.

The Potential Sale Reflects a Broader Healthcare M&A Recovery

Software dealmaking is picking up again

Reuters said software dealmaking has shown signs of recovery after the earlier concerns over AI disruption triggered a broad selloff. (Reuters)

That creates a potentially favorable environment for TPG if it decides to formally pursue a sale.

However, buyers remain cautious about valuations.

They are increasingly asking whether high-growth healthcare software companies can maintain their earnings and competitive advantages as AI changes the technology landscape.

Why This Matters

The possible Lyric sale highlights two major trends happening at the same time in healthcare.

The first is the growing importance of software that helps insurers manage healthcare costs.

The second is the disruption caused by AI to the economics of software itself.

Lyric sits directly at the intersection of those trends.

Its healthcare-specific data and relationships with major insurers could make the company highly valuable. At the same time, potential buyers need to determine whether AI-native competitors could eventually provide similar services for less money. (Reuters)

That tension will be central to how the company is valued.

Looking Ahead

TPG's sale exploration is still preliminary, and the company could ultimately decide not to sell Lyric.

If the process moves forward, potential buyers will likely focus heavily on several questions.

  • Can Lyric maintain its approximately $250 million annual EBITDA?
  • Can it continue growing revenue rapidly?
  • How defensible are its healthcare claims datasets?
  • Can its technology remain competitive as AI becomes more capable?

A successful sale around $5 billion would represent a substantial increase over TPG's $2.2 billion purchase price in 2022. It would also provide evidence that specialized healthcare software businesses can still command premium valuations despite broader concerns about AI disruption.

Key Takeaways

  • Private-equity firm TPG is exploring a sale of healthcare software company Lyric. (Reuters)
  • The company could be valued at around $5 billion.
  • TPG is working with JPMorgan Chase on the potential sale.
  • There is no guarantee that a transaction will happen. (Reuters)
  • Lyric helps insurers identify and prevent inaccurate medical claims payments.
  • Its customers include UnitedHealth, CVS and Humana. (Reuters)
  • TPG acquired the business, then called ClaimsXten, for about $2.2 billion in 2022.
  • The company was rebranded Lyric in 2023.
  • Lyric generates about $250 million in annual EBITDA, implying roughly a 20-times multiple at a $5 billion valuation. (Reuters)
  • TPG says the business has experienced a significant acceleration in revenue growth and benefited from AI.
  • Potential buyers are nevertheless concerned that AI-native competitors could perform similar functions more cheaply. (Reuters)
  • Public peer Claritev lost about 80% of its value between September 2025 and May 2026 amid concerns about AI disruption.
  • The potential deal illustrates the growing intersection of healthcare cost management, specialized software and AI.

What This Means for Healthcare Marketers

This story is especially relevant for companies selling into health insurers and healthcare-finance organizations.

Lyric's value comes from being connected to a problem insurers care deeply about: finding where healthcare dollars are being paid incorrectly. That makes its technology commercially valuable because it can be tied directly to financial outcomes, not just productivity.

The bigger market signal is the growing importance of data-rich healthcare software. Companies that can combine large healthcare datasets with AI and turn them into measurable financial improvements may become particularly attractive acquisition targets.

For healthcare marketers, this means looking beyond generic AI adoption. The stronger signal is where AI is being applied to a costly, measurable problem and whether the resulting product becomes embedded in a customer's day-to-day workflow.